Abiopharma

New Form 8-K - HCW Biologics Inc. Filed: 2025-05-15 AccNo: 0000950170-25-072700 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 144 - CYTOKINETICS INC Filed: 2025-05-15 AccNo: 0001950047-25-003059 Size: 4 KB

New Form 144 - PTC THERAPEUTICS, INC. Filed: 2025-05-15 AccNo: 0001959173-25-003233 Size: 7 KB

New Form 8-K - Surrozen, Inc./DE Filed: 2025-05-15 AccNo: 0000950170-25-072696 Size: 209 KB Item 5.07: Submission of Matters to a Vote of Security Holders

RETRANSMISSION - Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

New Form SCHEDULE 13G/A - 180 Life Sciences Corp. Filed: 2025-05-15 AccNo: 0000950170-25-072692 Size: 15 KB

New Form SCHEDULE 13G - Tourmaline Bio, Inc. Filed: 2025-05-15 AccNo: 0000950170-25-072694 Size: 6 KB

New Form SCHEDULE 13G/A - American Well Corp Filed: 2025-05-15 AccNo: 0001172661-25-002364 Size: 9 KB

New Form SCHEDULE 13G - Aligos Therapeutics, Inc. Filed: 2025-05-15 AccNo: 0001172661-25-002361 Size: 10 KB

New Form 4 - INSMED Inc Filed: 2025-05-15 AccNo: 0001628280-25-025947 Size: 12 KB

New Form 10-Q - Cardio Diagnostics Holdings, Inc. Filed: 2025-05-15 AccNo: 0001553350-25-000044 Size: 5 MB

Zomedica Announces First Quarter 2025 Financial Results: Revenue of $6.5 Million; 68% Gross Margin, and $65 Million in Liquidity to Support Growth

New Form 8-K - TuHURA Biosciences, Inc./NV Filed: 2025-05-15 AccNo: 0000950170-25-072685 Size: 269 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

SCYNEXIS Reports First Quarter 2025 FinancialResults and Provides Corporate Update

New Form SCHEDULE 13G - Neurogene Inc. Filed: 2025-05-15 AccNo: 0001104659-25-049481 Size: 21 KB